Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
J Appl Microbiol ; 135(6)2024 Jun 03.
Article de Anglais | MEDLINE | ID: mdl-38845374

RÉSUMÉ

AIMS: Carbapenemase-producing Klebsiella pneumoniae is categorized as a "critical global priority-one" pathogen by WHO and new and efficient treatment options are warranted. This study aims to assess the antibacterial and antibiofilm potential of N-acetyl cysteine (NAC), against clinical isolates of extensively drug resistant (XDR) K. pneumoniae and elucidate the mechanism of killing. METHODS AND RESULTS: XDR-K. pneumoniae were isolated from patients admitted to Madras Medical Mission Hospital, India. Antibiofilm activity of NAC was checked using in vitro continuous flow model and RNA sequencing was done using Illumina Novoseq. Data quality was checked using FastQC and MultiQC software. Our findings revealed that NAC at a concentration of 100 mg/ml was safe, and could inhibit the growth and completely eradicate mature biofilms of all XDR-K. pneumoniae isolates. Transcriptomic responses in XDR-K. pneumoniae to NAC showed significant downregulation of the genes associated with crucial biogenesis pathways, including electron transport chain and oxidoreductase activity besides a specific cluster of genes linked to ribosomal proteins. CONCLUSIONS: Our results indicate that NAC kills the XDR- K. pneumoniae clinical isolates by shutting the overall metabolism and, hence, successfully eradicate in vitro biofilms formed on catheters.


Sujet(s)
Acétylcystéine , Antibactériens , Biofilms , Multirésistance bactérienne aux médicaments , Klebsiella pneumoniae , Transcriptome , Biofilms/effets des médicaments et des substances chimiques , Klebsiella pneumoniae/effets des médicaments et des substances chimiques , Klebsiella pneumoniae/génétique , Antibactériens/pharmacologie , Acétylcystéine/pharmacologie , Humains , Multirésistance bactérienne aux médicaments/génétique , Infections à Klebsiella/microbiologie , Tests de sensibilité microbienne , Inde , Protéines bactériennes/génétique , Protéines bactériennes/métabolisme
2.
Nutrients ; 14(23)2022 Dec 01.
Article de Anglais | MEDLINE | ID: mdl-36501142

RÉSUMÉ

Surface-associated bacterial communities called biofilms are ubiquitous in nature. Biofilms are detrimental in medical settings due to their high tolerance to antibiotics and may alter the final pathophysiological outcome of many healthcare-related infections. Several innovative prophylactic and therapeutic strategies targeting specific mechanisms and/or pathways have been discovered and exploited in the clinic. One such emerging and original approach to dealing with biofilms is the use of human milk oligosaccharides (HMOs), which are the third most abundant solid component in human milk after lactose and lipids. HMOs are safe to consume (GRAS status) and act as prebiotics by inducing the growth and colonization of gut microbiota, in addition to strengthening the intestinal epithelial barrier, thereby protecting from pathogens. Moreover, HMOs can disrupt biofilm formation and inhibit the growth of specific microbes. In the present review, we summarize the potential of HMOs as antibacterial and antibiofilm agents and, hence, propose further investigations on using HMOs for new-age therapeutic interventions.


Sujet(s)
Microbiome gastro-intestinal , Lait humain , Humains , Lait humain/métabolisme , Oligosaccharides/pharmacologie , Oligosaccharides/métabolisme , Biofilms , Prébiotiques , Antibactériens/pharmacologie , Antibactériens/métabolisme
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...